Ropinirole
Unverricht-Lundborg Syndrome
University of TurkuSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Unverricht-Lundborg Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brivaracetam UCB Pharma SA | Phase 3 | BB |
Brv UCB Pharma | Phase 3 | BB |
HUMAN IMMUNOGLOBULINS Azienda Socio Sanitaria Territoriale di Mantova | Phase 3 | B |
Same molecule, other indications
Ropinirole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →